Baxter Home
Conditions Therapies Products Services About Baxter
Training and Education Sustainability Contact Us
 

The FLOLINK Valve:

Simplicity in Positive Displacement IV Valves

FLOLINK Positive Displacement Valve
FLOLINK offers clinicians all the advantages of positive displacement technology in a Luer-activated needleless device—and it is designed to help protect patients from contamination.
FLOLINK is:
  • Simple to swab—The flat, smooth surface is easily swabbed. This helps to prevent contamination, which can lead to infection.
  • Safe—Positive displacement minimizes fluid back flow and helps to maintain catheter patency.
  • Easy to use—FLOLINK can be used with a saline-only flush - heparin is not required to maintain catheter patency.


  SAFE FOR PATIENTS/CLINICIANS EASY FOR CLINICIANS
Dual-seal design Provides effective microbial barrier Prevents leakage
Saline-only flush (heparin optional) Eliminates risk of heparin-induced antibody reactions One less step required
Smooth, flat surface with no crevices Decreases risk of contamination Easy to swab and disinfect
No interstitial space No place within the valve where blood or fluid can become permanently trapped Easy to flush
Positive fluid pulse Reduces potential for occlusions, thus minimizing need to replace IV lines
  • Eliminates need for positive pressure flush technique (no clamping required during flush)
  • Allows direct connection to catheter
Non-latex, Non-DEHP Safe for latex sensitive patients; addresses DEHP concerns  
Needleless system Reduces risk of needlesticks
High flow rate (Avg. 10.4 L/Hr)* Allows for rapid fluid delivery
Lipid and blood compatible Flexible, single system for fluid delivery
No metal components MRI compatible
Appropriate for central and peripheral lines Simplifies training

 

*Tested at 39" head height with Baxter standard bore tubing and a two-piece Luer lock connector.

 

Rx only
For safe and proper use of this device, please refer to the complete instructions for use.
 
Copyright & Legal Disclaimer  |  Privacy  |   Print this page